Use of Biologics to Treat Psoriasis in HIV
Abstract
Standard treatments for moderate-to-severe, refractory psoriatic disease generally involve immunosuppressant medications, which can complicate treatment in patients with concomitant immune suppression, including human immunodeficiency virus (HIV) infection. HIV is uniformly an exclusion criterion for clinical trials of biologic therapy, leaving dermatologists with scant evidence to support clinical treatment decisions for this subpopulation of patients. Patients with HIV also experience healthcare related inequality in disproportionately higher levels compared to the general population. It is important for dermatologists to have some degree of knowledge and comfort treating and managing patients with significant, refractory psoriatic disease and comorbid HIV infection.
References
Menon K, Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(2):291-299. doi:10.1016/j.jaad.2009.03.047.
Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis. 2010;10(7):470-478. doi:10.1016/S1473-3099(10)70101-8.
Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol. 1994;31:372-5.
Zarbafian M, Cote B, Richer V. Treatment of moderate to severe psoriasis with apremilast over 2 years in the context of long-term treated HIV infection: A case report. SAGE Open Med Case Rep. 2019;7:2050313X19845193. Published 2019 May 6. doi:10.1177/2050313X19845193.
Shah BJ, Mistry D, Chaudhary N. Apremilast in People Living with HIV with Psoriasis Vulgaris: A Case Report. Indian J Dermatol. 2019;64(3):242-244. doi:10.4103/ijd.IJD_633_18.
Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc. 2000;75(10):1093-1098. doi:10.4065/75.10.1093.
Bardazzi F, Magnano M, Campanati A, et al. Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience. Acta Derm Venereol. 2017;97(8):989-990. doi:10.2340/00015555-2698.
Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67(5):710-712. doi:10.1136/ard.2007.081513.
De Simone C, Perino F, Caldarola G, D’Agostino M, Peris K. Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports. J Int Med Res. 2016;44(1 suppl):67-71. doi:10.1177/0300060515593250.
Di Lernia V, Zoboli G, Ficarelli E. Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept. Indian J Dermatol Venereol Leprol. 2013;79(3):444. doi:10.4103/0378-6323.110807.
Lee ES, Heller MM, Kamangar F, Park KK, Koo JY. Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study. J Drugs Dermatol. 2012;11(3):413-414.
Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. The Journal of rheumatology. 2007;34(6):1353-1355.
Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Archives of dermatology. 2008;144(4):453-456.
Paparizos V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat. 2012;23(6):398-399. doi:10.3109/09546634.2011.579085.
Lindsey SF, Weiss J, Lee ES, Romanelli P. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient. J Drugs Dermatol. 2014;13(7):869-871.
Saeki H, Ito T, Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015;29(8):1653-1655. doi:10.1111/jdv.12531.
Bartke U, Venten I, Kreuter A, Gubbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab [published correction appears in Br J Dermatol. 2004 Jun;150(6):1235. Gabbay S [corrected to Gubbay S]. Br J Dermatol. 2004;150(4):784-786. doi:10.1111/j.0007-0963.2004.05885.x.
Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine. 2007;74(2):197-200. doi:10.1016/j.jbspin.2006.05.012.
Wangsiricharoen S, Ligon C, Gedmintas L, et al. Rates of Serious Infections in HIV-Infected Patients Receiving Tumor Necrosis Factor Inhibitor Therapy for Concomitant Autoimmune Diseases. Arthritis Care Res (Hoboken). 2017;69(3):449-452. doi:10.1002/acr.22955.
Wang DM, Fernandez AP, Calabrese CM, Calabrese LH. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Clin Exp Dermatol. 2019;44(1):113-115. doi:10.1111/ced.13630.
Wieder S, Routt E, Levitt J, Lebwohl M. treatment of refractory psoriasis with ustekinumab in an hiv-positive patient: A case presentation and review of the biologic Literature. In Psoriasis Forum. 2014 Sep;20(3):96-102. Sage CA: Los Angeles, CA: SAGE Publications.
Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Dtsch Dermatol Ges. 2019;17(6):646-648. doi:10.1111/ddg.13851.
Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of guselkumab used and review. Dermatol Online J. 2018;24(11):13030/qt3db748cg. Published 2018 Nov 15.
Fink DL et al. Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals. Int J STD AIDS. 2017;28:110–9. PMID: 27733707
Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74(5):974-980. doi:10.1016/j.jaad.2015.11.043.
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27–40. PMID: 30017705.
Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43–53. PMID: 30017706.
Nakamura M et al. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018 Jan;101(1):38;42;56. PMID: 29529104.
